Tue, Apr 15, 8:02 PM (32 days ago)
**Jaguar Health, Inc. (JAGX)** filed an amendment to its 10-K for the fiscal year ended December 31, 2024. The amendment focuses on updating Part III, Items 10 through 14, which include information on directors, executive officers, corporate governance, executive compensation, security ownership, related transactions, and accounting fees. The amendment was necessary because the company did not intend to file a definitive proxy statement within 120 days of December 31, 2024. **Key Points:** 1. **Corporate Governance:** - The board of directors is divided into three classes with staggered three-year terms. - The board has three committees: Audit, Compensation, and Nominating. - The board is composed of five directors, with four considered independent. 2. **Executive Compensation:** - The company provided a summary compensation table for named executive officers, detailing salaries, bonuses, option awards, stock awards, and other compensation. - The total compensation for the CEO, Lisa Conte, was $875,320 in 2024. - Other executives received varying amounts, with the highest being $646,627 for Pravin Chaturvedi. 3. **Security Ownership:** - The table lists beneficial ownership of common stock for directors, executive officers, and certain beneficial owners. - Lisa Conte holds 2.8% of the outstanding shares, while James J. Bochnowski holds 7.5%. 4. **Related Transactions:** - The company engaged in several transactions with related parties, including exchanges of common stock for reductions in outstanding balances of royalty interests and notes. - Significant transactions include exchanges with Iliad and Streeterville, involving millions of dollars and thousands of shares. 5. **Accounting Fees:** - RBSM LLP served as the independent registered public accounting firm, with fees totaling $558,500 for 2024. - The Audit Committee pre-approved all audit and non-audit services. 6. **Future Outlook and Risk Factors:** - The amendment does not provide detailed financial performance, revenue, net income, or earnings per share for 2024. - The company's financial condition and market position changes are not explicitly stated in the provided text. **Conclusion:** The amendment primarily updates corporate governance and executive compensation details. It does not provide comprehensive financial performance data for 2024. The company's strategic overview and future outlook are not explicitly discussed in the provided text.